Overview of Libtayo, First FDA-Approved Drug for Metastatic Cutaneous Squamous Cell Carcinoma (CSCC) When Surgery or Radiation Isn’t an Option

[3] Libtayo and other immune checkpoint inhibitors are types of monoclonal antibodies . They work by blocking checkpoint proteins, which act like switches to turn your immune response on or off. It attaches to proteins called PD-L1 proteins on normal cells, telling your body to avoid them. Libtayo and other PD-1 inhibitors can block PD-1 from binding, boosting your immune response against cancer cells. Other types of PD-1 inhibitors include nivolumab (Opdivo and Opdivo Qvantig) and pembrolizumab (Keytruda and Keytruda Qlex).